Unknown

Dataset Information

0

FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.


ABSTRACT: The efficacy of oxaliplatin-based chemotherapy combined with anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) remains controversial in metastatic colorectal cancer (mCRC). This meta-analysis aims to estimate the effect of adding panitumumab or cetuximab to oxaliplatin-based chemotherapy in RAS wild type mCRC patients for the first-line treatment. The primary tumor location is also considered into this meta-analysis.RCT studies were identified by a search of MEDLINE, EMBASE, Cochrane library to October 2017, supplemented by manually retrieving ASCO, ESMO conference abstracts. The pooled hazard ratio (HR) for progression-free survival (PFS) and overall survival (OS), and pooled odds ratios (OR) for the overall response rate (ORR) were calculated by Review Manager 5.3.The results indicated that the addition of anti-EGFR mAbs to FOLFOX regimen in RAS wild-type mCRC patients for the first-line treatment resulted in considerable improvements in PFS (HR?=?0.70; 95% confidence interval [CI]: 0.59-0.82; P?

SUBMITTER: Chen D 

PROVIDER: S-EPMC5882422 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.

Chen Datian D   Li Li L   Zhang Xiang X   Gao Guangyi G   Shen Lili L   Hu Jing J   Yang Mi M   Liu Baorui B   Qian Xiaoping X  

Medicine 20180301 10


<h4>Background</h4>The efficacy of oxaliplatin-based chemotherapy combined with anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) remains controversial in metastatic colorectal cancer (mCRC). This meta-analysis aims to estimate the effect of adding panitumumab or cetuximab to oxaliplatin-based chemotherapy in RAS wild type mCRC patients for the first-line treatment. The primary tumor location is also considered into this meta-analysis.<h4>Methods</h4>RCT studies were identif  ...[more]

Similar Datasets

| S-EPMC8018298 | biostudies-literature
| S-EPMC8895744 | biostudies-literature
| S-EPMC8127841 | biostudies-literature
| S-EPMC6913322 | biostudies-literature
| S-EPMC8955035 | biostudies-literature
| 2322407 | ecrin-mdr-crc
| S-EPMC4248572 | biostudies-literature
| S-EPMC7726112 | biostudies-literature
| S-EPMC4176068 | biostudies-other
| S-EPMC5784655 | biostudies-literature